Scandion Oncology was formed as a spin-out company from the University of Copenhagen and the research and development company Saniona AB in 2017 for the purpose of addressing one of the greatest challenges in modern oncology – the effective treatment of cancer which is or has become resistant to the prescribed cancer-fighting drugs. In preclinical animal studies, the company’s leading drug candidate, SCO-101, has been found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. Furthermore, it has been shown in vitro-studies that SCO-101 significantly restores chemotherapy sensitivity in resistant cells.

Quotes for Scandion Oncology

Right Now

+/-
%
0,00%
Latest
High
Low
Volume
0
Turnover (SEK)
0
Value (MSEK)
83,1

Board

CEO

  • Nils Brünner

Chairman Of The Board

  • Jørgen Bardenfleth

Board

  • Jørgen Bardenfleth
  • Carl Borrebaeck
  • Christian Vinding Thomsen
  • Thomas Feldthus

Videos

Key Numbers

*Compiled data from Inquiry Financial

Upcoming reports

  • 2019-05-23 Interim Report Q1

  • 2019-05-29 Annual General Meeting

  • 2019-08-22 Half Year Report

  • 2019-11-21 Interim Report Q3

  • 2020-02-20 Year End Report